Zou T, Mao X, Yin J, Li X, Chen J, Zhu T, Li Q, Zhou H, Liu Z
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China.
Clin Genet. 2017 Apr;91(4):520-528. doi: 10.1111/cge.12908. Epub 2016 Nov 24.
The Ras-related C3 botulinum toxin substrate 1 (RAC1), a member of the Rho family of small guanosine triphosphatases, is critical for many cellular activities, such as phagocytosis, adhesion, migration, motility, cell proliferation, and axonal growth. In addition, RAC1 plays an important role in cancer angiogenesis, invasion, and migration, and it has been reported to be related to most cancers, such as breast cancer, gastric cancer, testicular germ cell cancer, and lung cancer. Recently, the therapeutic target of RAC1 in cancer has been investigated. In addition, some investigations have shown that inhibition of RAC1 can reverse drug-resistance in non-small cell lung cancer. In this review, we summarize the recent advances in understanding the role of RAC1 in lung cancer and the underlying mechanisms and discuss its value in clinical therapy.
Ras相关的C3肉毒杆菌毒素底物1（RAC1）是小GTP酶Rho家族的成员之一，对许多细胞活动至关重要，如吞噬作用、黏附、迁移、运动、细胞增殖和轴突生长。此外，RAC1在癌症血管生成、侵袭和迁移中起重要作用，据报道它与大多数癌症有关，如乳腺癌、胃癌、睾丸生殖细胞癌和肺癌。最近，RAC1在癌症中的治疗靶点已被研究。此外，一些研究表明，抑制RAC1可以逆转非小细胞肺癌的耐药性。在这篇综述中，我们总结了近年来在理解RAC1在肺癌中的作用及其潜在机制方面取得的进展，并讨论了其在临床治疗中的价值。
Zotero 插件